Lv3
348 积分 2025-11-17 加入
Discovery of BIIB068: A Selective, Potent, Reversible Bruton’s Tyrosine Kinase Inhibitor as an Orally Efficacious Agent for Autoimmune Diseases
2天前
已完结
A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models
1个月前
已完结
Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib
1个月前
已完结
Renal-targeted drug delivery: overcoming barriers and charting the course
2个月前
已完结
Small-molecule BTK inhibitors: From discovery to clinical application
2个月前
已完结
Design and Synthesis of Fsp3‐Enriched Spirocyclic‐Based Biological Screening Compound Arrays via DOS Strategies and Their NNMT Inhibition Profiling
2个月前
已完结
Population Pharmacokinetic and Exposure-Response Modeling Supports BI 764198 20 mg as the Therapeutic Dose for Phase 3, with No Dose Adjustment Required
2个月前
已关闭
Small molecule inhibitors of mannan-binding lectin-associated serine Proteases-2 and-3
2个月前
已完结
TRPC6 inhibition for the treatment of focal segmental glomerulosclerosis: a randomised, placebo-controlled, phase 2 trial of BI 764198
3个月前
已完结
皖公网安备34019202002308
